$13.30
+7.5%ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
CLPT โข NASDAQ
| ClearPoint Neuro, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||
-25.5M | -18.9M | -22.1M | -16.4M | -14.4M | -6.8M | -5.5M | -6.2M | -7.2M | -8.1M | -8.4M | -4.5M | -7.1M | -5.7M | -8.3M | -9.5M | |
982K | 1.9M | 1.5M | 777K | 692K | 553K | 250.6K | 109.4K | 116.5K | 155.7K | 211.9K | 377.3K | 426.2K | 417K | 354.9K | 266.2K | |
0.0 | 0.0 | 0.0 | 0.0 | 202K | -896K | 0.0 | -64.3K | -24.2K | -252.3K | -1.5M | -5.6M | -664.1K | 2.1M | 0.0 | 1.5M | |
8.2M | 6.9M | 6.1M | 0.0 | 2.1M | 1.1M | 799.1K | 1.2M | 1.2M | 959.6K | 1.7M | 880.8K | 1.5M | 2M | 989.9K | 245.5K | |
2.3M | -245K | 2.2M | 3.8M | 425K | 893K | 729.3K | 640K | 928.4K | 714.7K | 617.1K | 411.5K | 140.3K | 124.6K | 1.4M | 29.7K | |
(0.0) | (62K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (49.3K) | |
-9.8M | 1.4M | -1.4M | -4.3M | -1.7M | -2.7M | 911.3K | -383.7K | -1.1M | 672.2K | -1.2M | 1.2M | -2.1M | -6.4M | -632.7K | -245.2K | |
-23.9M | -9M | -13.7M | -16.2M | -12.7M | -7.8M | -2.8M | -4.6M | -6M | -5.8M | -8.6M | -7.3M | -7.8M | -7.4M | -6.2M | -7.7M | |
INVESTING ACTIVITIES | ||||||||||||||||
-522K | -275K | -717K | -1.1M | -168K | -482K | -160.2K | -63.5K | -26.8K | -101K | -76.9K | -48.1K | -174.5K | -127.5K | -26.1K | -61.7K | |
(1.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | -21.6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 12M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 9.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -100K | 0.0 | 0.0 | 0.0 | |
(615K) | -275K | (8.9M) | -10.7M | -168K | -482K | -160.2K | -63.5K | -26.8K | -101K | -76.9K | -48.1K | -174.5K | -127.5K | -26.1K | -61.7K | |
FINANCING ACTIVITIES | ||||||||||||||||
3.9M | 16.1M | -210K | 745K | 46.8M | 376K | 7.4M | 0.0 | 12M | 3.8M | 4.9M | 12.9M | 9.8M | 5.5M | 2.8M | 3M | |
48.1M | -10M | 0.0 | 0.0 | 0.0 | 22.3M | -2.1M | -2M | 0.0 | 0.0 | 0.0 | 3.5M | 0.0 | 3.4M | 2M | 3.8M | |
(0.0) | (0.0) | -210K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -4.8K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.9M | 40K | 506K | -336K | 90K | 1K | 313.3K | 505.4K | 0.0 | -4.8K | 0.0 | 9.5M | 19.6K | 94.4K | 2.3K | 0.0 | |
50.2M | 6.2M | 296K | 409K | 46.9M | 22.7M | 5.6M | -1.5M | 12M | 3.8M | 4.9M | 13M | 9.8M | 9M | 4.8M | 6.8M | |
CASH FLOW SUMMARY | ||||||||||||||||
26.9M | -3M | -4.5M | -26.5M | 34M | 14.4M | 2.6M | -6.2M | 6M | -2.1M | -3.8M | 5.7M | 1.9M | 1.5M | -1.4M | -991.8K | |
20.1M | 23.1M | 27.6M | 54.1M | 20.1M | 5.7M | 3.1M | 9.3M | 3.3M | 5.4M | 9.2M | 3.5M | 1.6M | 145.5K | 1.6M | 2.6M | |
47M | 20.1M | 23.1M | 27.6M | 54.1M | 20.1M | 5.7M | 3.1M | 9.3M | 3.3M | 5.4M | 9.2M | 3.5M | 1.6M | 145.5K | 1.6M | |
-24.4M | -9.2M | -14.4M | -16.4M | -12.9M | -8.3M | -3M | -4.7M | -6M | -5.9M | -8.7M | -7.3M | -8M | -7.6M | -6.3M | -7.8M |
CLPT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | February 05, 2026 | November 20, 2025 | 2025 | |
S-3 S-3 N/A | January 14, 2026 | January 14, 2026 | ย | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 |
Continue your CLPT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.